CJC-1295 with DAC 2 mg

CJC-1295 with DAC 2 mg is Hilma Biocare's long-acting growth-hormone-releasing hormone analogue, supplied as a single lyophilised vial. The Drug Affinity Complex extends its half-life dramatically, producing sustained growth-hormone and IGF-1 elevation.

What CJC-1295 with DAC Is

CJC-1295 is a modified analogue of growth-hormone-releasing hormone, the hypothalamic peptide that stimulates pituitary GH release. The DAC modification adds a maleimide group that covalently binds the peptide to albumin in the bloodstream, protecting it from rapid clearance. That albumin binding is what separates it from short-acting analogues such as mod GRF 1-29. The 2 mg vial is the standard presentation.

The History of CJC-1295

CJC-1295 was developed by ConjuChem in the early 2000s using its Drug Affinity Complex technology. A clinical study published in 2005 showed that a single dose produced sustained increases in growth hormone and IGF-1 lasting for days, a striking result compared with native GHRH. The compound became a reference long-acting GHRH analogue in endocrine research, though it was never approved as a medicine.

How It Works

After reconstitution and administration, the maleimide group forms a covalent bond with the cysteine-34 residue of albumin. The albumin-peptide complex circulates for an extended period and gradually releases active peptide, which binds GHRH receptors on pituitary somatotrophs and stimulates GH secretion. The result is a sustained rise in GH and IGF-1 rather than a short pulse. The peptide is eventually cleared through normal protein turnover.

What the Research Shows

• Early clinical work showed a single dose raised GH and IGF-1 for days.
• The albumin-binding mechanism is a well-documented example of half-life extension.
• GHRH analogues are studied for their effects on pituitary GH output.
• Long-term human data remains limited.

Research Context

The DAC technology behind CJC-1295 is a useful case study in half-life extension. By forming a covalent bond with albumin, the peptide avoids the rapid renal clearance that limits native GHRH to minutes. Early clinical work reported elevated growth hormone and IGF-1 for up to a week after a single dose, which was unprecedented for a GHRH analogue. The trade-off is that the prolonged action cannot be quickly reversed, and injection-site reactions were reported in trials. Those characteristics shape how the compound is used in research.

Strength, Pack and Authentication

Each vial contains 2 mg of lyophilised CJC-1295 with DAC, sealed and packed in a printed carton stating the compound, strength and vial count. A scratch-off security code inside the box links the pack to Hilma Biocare's records. The powder is stable before reconstitution and intended for research use only.

Buying CJC-1295 Online

CJC-1295 with DAC is one of the most searched GHRH analogues. If you are researching CJC-1295, comparing long-acting GHRH products or looking to buy CJC-1295 online from a trusted Hilma Biocare supplier, this page gives you the full specification, pack size, price and live stock status. Browse more Hilma Biocare peptides at NotNatty.